Capecitabine with chemotherapy improves survival in breast cancer patients: Study

2. Cox regression analysis of all patients included found that the addition of capecitabine had no meaningful effect on disease-free survival when compared to therapy without capecitabine.

3. In the subset of studies when capecitabine was used instead of another medication, there was no effect on disease-free survival.

4. However, adding capecitabine to the conventional systemic therapy enhanced disease-free survival.

5. The overall cohort and the capecitabine-added subset both saw an improvement in overall survival.

6. In terms of disease-free survival and overall survival, subgroup analysis demonstrated that triple-negative breast cancer patients benefited from capecitabine therapy both overall and in combination with other systemic therapies.

In conclusion, this study points out the efficiency of Capecitabine in disease-free survival and overall survival and should be regularly advised by physicians to their patients.

Reference: van Mackelenbergh, M. T., Seither, F., Möbus, V., O'Shaughnessy, J., Martin, M., Joensuu, H., Untch, M., Nitz, U., Steger, G. G., Miralles, J. J., Barrios, C. H. Effects of capecitabine as part of neo-/adjuvant chemotherapy – A meta-analysis of individual breast cancer patient data from 13 randomised trials including 15,993 patients. In European Journal of Cancer (Vol. 166, pp. 185–201). Elsevier BV. https://doi.org/10.1016/j.ejca.2022.02.003